Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Tuberculosis

Free Subscription Articles published in Eur Respir J Retrieve available abstracts of 95 articles: HTML format

Single Articles

April 2024
1. NOGUERA-JULIAN A, Latre C, Flores A
   Availability of paediatric dispersible fixed-dose combinations of tuberculosis drugs in Spain.
   Eur Respir J. 2024;63:2400104.
   PubMed    
   
   
   January 2024
2. ALI M, El Hafid M, Farrar DS, Kourdi H, et al
   Travel-acquired paediatric tuberculosis in the Greater Toronto Area, Canada, 2002-2018.
   Eur Respir J. 2024 Jan 11:2301533. doi: 10.1183/13993003.01533-2023.
   PubMed    
   
   
   
3. 
   "Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update." S. Ghosh, L. Breitscheidel, N. Lazarevic, et al. Eur Respir J 2021; 57: 2002483.
   Eur Respir J. 2024;63:2052483.
   PubMed    
   
   
   November 2023
4. ACHAR J, Seddon JA, Knight GM, Dodd PJ, et al
   Guiding pragmatic treatment choices for rifampicin-resistant tuberculosis in the absence of second-line drug susceptibility testing.
   Eur Respir J. 2023 Nov 9:2300969. doi: 10.1183/13993003.00969-2023.
   PubMed    
   
   
   
5. PERUMAL R, Bionghi N, Nimmo C, Letsoalo M, et al
   Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: A systematic review and meta-analysis.
   Eur Respir J. 2023 Nov 9:2300639. doi: 10.1183/13993003.00639-2023.
   PubMed    
   
   
   
6. ZENNER D, Cobelens F, Abubakar I
   Reply: Tuberculosis screening in migrants to the EU/EEA and UK.
   Eur Respir J. 2023;62:2301535.
   PubMed    
   
   
   
7. KOHLER N, Vasiliu A, Mandalakas AM, Martinez L, et al
   Tuberculosis screening in migrants to the EU/EEA and UK.
   Eur Respir J. 2023;62:2301230.
   PubMed    
   
   
   
8. DIEL R, Schluger NW
   Long-term outcome of co-infection of COVID-19 and tuberculosis: the "cursed duet".
   Eur Respir J. 2023;62:2301881.
   PubMed    
   
   
   
9. CASCO N, Jorge AL, Palmero DJ, Alffenaar JW, et al
   Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort.
   Eur Respir J. 2023;62:2300925.
   PubMed     Abstract available
   
   
   October 2023
10. DEN BOON S, Yedilbayev A
    Screening for tuberculosis among migrants in Europe: harmonising approaches during a humanitarian crisis?
    Eur Respir J. 2023;62:2301537.
    PubMed    
    
    
    
11. AGUIAR SOARES K, Ehrlich J, Camara M, Chaloub S, et al
    Implementation of WHO guidelines on urine lateral flow LAM testing in high TB/HIV burden African countries.
    Eur Respir J. 2023;62:2300556.
    PubMed    
    
    
    
12. ZENNER D, Brals D, Nederby-Ohd J, Menezes D, et al
    Drivers determining tuberculosis disease screening yield in four European screening programmes: a comparative analysis.
    Eur Respir J. 2023;62:2202396.
    PubMed     Abstract available
    
    
    September 2023
13. RIOU C, du Bruyn E, Kim GHJ, da Costa I, et al
    Derivation of a high-resolution CT-based, semi-automated radiographic score in tuberculosis and its relationship to bacillary load and antitubercular therapy.
    Eur Respir J. 2023 Sep 7:2300600. doi: 10.1183/13993003.00600-2023.
    PubMed    
    
    
    
14. BYRNE A, Allwood B, Schoeman I, Johnston J, et al
    "Post tuberculosis": the urgent need for inclusion of lung health outcomes in tuberculosis treatment trials.
    Eur Respir J. 2023;62:2300950.
    PubMed     Abstract available
    
    
    August 2023
15. STOCKER SL, Alffenaar JC
    Predicting early bactericidal activity using pre-clinical data for tuberculosis drugs: a platform for model-informed drug discovery and development.
    Eur Respir J. 2023;62:2301108.
    PubMed    
    
    
    
16. ERNEST JP, Goh JJN, Strydom N, Wang Q, et al
    Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs.
    Eur Respir J. 2023;62:2300165.
    PubMed     Abstract available
    
    
    June 2023
17. MIGLIORI GB, Dowdy D, Denholm JT, D'Ambrosio L, et al
    The path to tuberculosis elimination: a renewed vision.
    Eur Respir J. 2023;61:2300499.
    PubMed     Abstract available
    
    
    
18. 
    June Podcast: Path to tuberculosis elimination.
    Eur Respir J. 2023;61:23E6106.
    PubMed    
    
    
    May 2023
19. KOSER CU, Maurer FP
    Minimum inhibitory concentrations and sequencing data have to be analysed in more detail to set provisional epidemiological cut-off values for Mycobacterium tuberculosis complex.
    Eur Respir J. 2023;61:2202397.
    PubMed    
    
    
    
20. 
    Reply: Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis.
    Eur Respir J. 2023;61:2300426.
    PubMed     Abstract available
    
    
    
21. KAHLMETER G, Turnidge J
    The determination of epidemiological cut-off values requires a systematic and joint approach based on quality controlled, non-truncated minimum inhibitory concentration series.
    Eur Respir J. 2023;61:2202259.
    PubMed    
    
    
    November 2022
22. OTTO-KNAPP R, Hacker B, Krieger D, Stete K, et al
    Long-term multidrug- and rifampicin-resistant tuberculosis treatment outcome by new WHO definitions in Germany.
    Eur Respir J. 2022;60:2200765.
    PubMed    
    
    
    September 2022
23. KIM C, Ko Y, Moon JW, Park YB, et al
    Incidence, risk factors, and final causes for misdiagnosis of tuberculosis in the Republic of Korea: a population-based longitudinal analysis.
    Eur Respir J. 2022 Sep 14. pii: 13993003.01461-2022.
    PubMed    
    
    
    August 2022
24. SALUZZO F, Denkinger CM, Cirillo DM
    Improving interferon-gamma release assay interpretation: are IP-10 and MIG the solution?
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
25. ROCHE N, Crichton ML, Goeminne PC, Cao B, et al
    Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    July 2022
26. MATTEELLI A, Alffenaar JC
    Diagnosis and treatment of tuberculosis infection: can it contribute to achieving tuberculosis elimination?
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
27. MASINI T, Kanchar A, Mirzayev F, Viney K, et al
    Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally.
    Eur Respir J. 2022 Jul 1. pii: 13993003.01227-2022.
    PubMed    
    
    
    June 2022
28. CHUNG C, Shin JE, Jeon D, Kang H, et al
    Treatment outcomes of multidrug-resistant tuberculosis with chronic kidney/liver disease.
    Eur Respir J. 2022 Jun 16. pii: 13993003.00930-2022.
    PubMed    
    
    
    May 2022
29. MANTEI A, Meyer T, Schurmann M, Bessler C, et al
    Mycobacterium tuberculosis-specific CD4 T-cell scoring discriminates tuberculosis infection from disease.
    Eur Respir J. 2022 May 26. pii: 13993003.01780-2021.
    PubMed     Abstract available
    
    
    
30. AHMED M, Tezera LB, Elkington PT, Leslie AJ, et al
    The paradox of immune checkpoint inhibition reactivating tuberculosis.
    Eur Respir J. 2022 May 20. pii: 13993003.02512-2021.
    PubMed     Abstract available
    
    
    
31. GUGLIELMETTI L, Gunther G, Leu C, Cirillo D, et al
    Rifapentine access in Europe: growing concerns over key tuberculosis treatment component.
    Eur Respir J. 2022;59.
    PubMed    
    
    
    
32. SPRUIJT I, Joren C, Schimmel H, Procee F, et al
    The identification of prevalent tuberculosis disease through infection screening among high-risk migrants in the Netherlands.
    Eur Respir J. 2022;59.
    PubMed    
    
    
    April 2022
33. DAHL V, Migliori GB, Lange C, Wejse C, et al
    War in Ukraine: an immense threat to the fight against tuberculosis.
    Eur Respir J. 2022;59.
    PubMed    
    
    
    
34. 
    Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment.
    Eur Respir J. 2022;59.
    PubMed    
    
    
    March 2022
35. 
    Epidemiological cutoff values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis.
    Eur Respir J. 2022 Mar 17. pii: 13993003.00239-2022.
    PubMed     Abstract available
    
    
    
36. MIGLIORI GB, Falzon D, Marks GB, Goletti D, et al
    Commemorating World Tuberculosis Day 2022: recent ERJ articles of critical relevance to ending TB and saving lives.
    Eur Respir J. 2022;59.
    PubMed    
    
    
    
37. TORNHEIM JA, Udwadia ZF, Arora PR, Gajjar I, et al
    Cycloserine did not increase depression incidence or severity at standard dosing for multidrug-resistant tuberculosis.
    Eur Respir J. 2022;59.
    PubMed    
    
    
    February 2022
38. DINARDO AR, Gandhi T, Heyckendorf J, Grimm SL, et al
    Gene expression signatures identify biologically and clinically distinct tuberculosis endotypes.
    Eur Respir J. 2022 Feb 15. pii: 13993003.02263-2021.
    PubMed     Abstract available
    
    
    January 2022
39. MARGINEANU I, Akkerman O, Cattaneo D, Goletti D, et al
    Practices of therapeutic drug monitoring in tuberculosis - an international survey.
    Eur Respir J. 2022 Jan 27. pii: 13993003.02787-2021.
    PubMed    
    
    
    
40. FALZON D, den Boon S, Kanchar A, Zignol M, et al
    Global reporting on tuberculosis preventive treatment among contacts.
    Eur Respir J. 2022 Jan 27. pii: 13993003.02753-2021.
    PubMed    
    
    
    
41. UZORKA JW, Bakker JA, van Meijgaarden KE, Leyten EMS, et al
    Biomarkers to identify Mycobacterium tuberculosis-infection among borderline QuantiFERON results.
    Eur Respir J. 2022 Jan 20. pii: 13993003.02665-2021.
    PubMed     Abstract available
    
    
    November 2021
42. GHODOUSI A, Rizvi AH, Khanzada FM, Akhtar N, et al
    In vivo Microevolution of Mycobacterium tuberculosis and transient emergence of atpE_Ala63Pro mutation during treatment in a pre-XDR TB patient.
    Eur Respir J. 2021 Nov 18. pii: 13993003.02102-2021.
    PubMed    
    
    
    
43. 
    Tuberculosis and COVID-19 co-infection: description of the global cohort.
    Eur Respir J. 2021 Nov 11. pii: 13993003.02538-2021.
    PubMed     Abstract available
    
    
    
44. XIN H, Cao X, Zhang H, Feng B, et al
    Protective efficacy of 6-week regimen for latent tuberculosis infection treatment in rural China: 5-year follow-up of a randomised controlled trial.
    Eur Respir J. 2021 Nov 11. pii: 13993003.02359-2021.
    PubMed     Abstract available
    
    
    
45. ZHENG X, Davies Forsman L, Bao Z, Xie Y, et al
    Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug resistant tuberculosis: a multi-centre prospective cohort study in China.
    Eur Respir J. 2021 Nov 4. pii: 13993003.01925-2021.
    PubMed     Abstract available
    
    
    October 2021
46. GUPTE AN, Kumar P, Araujo-Pereira M, Kulkarni V, et al
    Baseline IL-6 is a biomarker for unfavorable tuberculosis treatment outcomes: a multi-site discovery and validation study.
    Eur Respir J. 2021 Oct 28. pii: 13993003.00905-2021.
    PubMed     Abstract available
    
    
    
47. SALUZZO F, Mantegani P, Poletti de Chaurand V, Cirillo DM, et al
    QIAreach QuantiFERON(R)-TB for the diagnosis of M. tuberculosis infection.
    Eur Respir J. 2021 Oct 21. pii: 13993003.02563-2021.
    PubMed    
    
    
    September 2021
48. SPRUIJT I, Joren C, van den Hof S, Erkens C, et al
    Tailored approaches facilitate high completion of tuberculosis infection treatment among migrants.
    Eur Respir J. 2021 Sep 24. pii: 13993003.02077-2021.
    PubMed    
    
    
    
49. DECROO T, Jai K, Aung M, Hossain MA, et al
    Bedaquiline can act as core drug in a standardized treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis.
    Eur Respir J. 2021 Sep 24. pii: 13993003.02124-2021.
    PubMed    
    
    
    
50. CHESOV E, Chesov D, Maurer FP, Andres S, et al
    Emergence of bedaquiline-resistance in a high-burden country of tuberculosis.
    Eur Respir J. 2021 Sep 9. pii: 13993003.00621-2021.
    PubMed     Abstract available
    
    
    August 2021
51. MIGLIORI GB, Thong PM, Alffenaar JW, Denholm J, et al
    Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study.
    Eur Respir J. 2021 Aug 26. pii: 13993003.01786-2021.
    PubMed    
    
    
    
52. LINH NN, Viney K, Gegia M, Falzon D, et al
    World Health Organization treatment outcome definitions for tuberculosis: 2021 update.
    Eur Respir J. 2021;58.
    PubMed    
    
    
    July 2021
53. ALAGNA R, Cabibbe AM, Miotto P, Saluzzo F, et al
    Is the new WHO definition of extensively drug-resistant tuberculosis easy to apply in practice?
    Eur Respir J. 2021;58.
    PubMed    
    
    
    
54. TE BRAKE LHM, de Jager V, Narunsky K, Vanker N, et al
    Increased bactericidal activity but dose-limiting intolerability at 50 mg.kg(-1) rifampicin.
    Eur Respir J. 2021;58.
    PubMed     Abstract available
    
    
    June 2021
55. KHAN PY, Franke MF, Hewison C, Seung KJ, et al
    All-oral longer regimens are effective for the management of multidrug resistant tuberculosis in high burden settings.
    Eur Respir J. 2021 Jun 17. pii: 13993003.04345-2020.
    PubMed     Abstract available
    
    
    
56. SAAVEDRA B, Mambuque E, Nguenha D, Gomes N, et al
    Performance of Xpert MTB/RIF Ultra for tuberculosis diagnosis in the context of passive and active case finding.
    Eur Respir J. 2021 Jun 17. pii: 13993003.00257-2021.
    PubMed     Abstract available
    
    
    
57. ORIKIRIZA P, Smith J, Ssekyanzi B, Nyehangane D, et al
    Tuberculosis diagnostic accuracy of stool Xpert MTB/RIF and urine AlereLAM in vulnerable children.
    Eur Respir J. 2021 Jun 17. pii: 13993003.01116-2021.
    PubMed     Abstract available
    
    
    
58. SHIVAKOTI R, Newman JW, Hanna LE, Queiroz ATL, et al
    Host Lipidome and Tuberculosis Treatment Failure.
    Eur Respir J. 2021 Jun 17. pii: 13993003.04532-2020.
    PubMed     Abstract available
    
    
    
59. VILLA S, Tagliani E, Borroni E, Castellotti PF, et al
    Outbreak of pre- and extensively drug-resistant tuberculosis in northern italy: urgency of cross-border, multidimensional, surveillance systems.
    Eur Respir J. 2021 Jun 3. pii: 13993003.00839-2021.
    PubMed    
    
    
    
60. GUGLIELMETTI L, Varaine F
    The coming-of-age of bedaquiline: a tale with an open ending.
    Eur Respir J. 2021;57.
    PubMed    
    
    
    May 2021
61. PENN-NICHOLSON A, Gomathi SN, Ugarte-Gil C, Meaza A, et al
    A prospective multicentre diagnostic accuracy study for the Truenat tuberculosis assays.
    Eur Respir J. 2021 May 28. pii: 13993003.00526-2021.
    PubMed     Abstract available
    
    
    
62. NOGUERA-JULIAN A, Buonsenso D, Mckenna L, Seddon JA, et al
    Availability of fixed-dose, child-friendly formulations of first-line tuberculosis drugs in Europe.
    Eur Respir J. 2021 May 28. pii: 13993003.01196-2021.
    PubMed    
    
    
    
63. VELEN K, Shingde RV, Ho J, Fox GJ, et al
    The effectiveness of contact investigation among contacts of tuberculosis patients: a systematic review and meta-analysis.
    Eur Respir J. 2021 May 20. pii: 13993003.00266-2021.
    PubMed     Abstract available
    
    
    
64. WEE LE, Goh KCM, Conceicao EP, Tan JBX, et al
    Increased detection of pulmonary tuberculosis amongst hospitalised inpatients during the COVID-19 pandemic.
    Eur Respir J. 2021;57.
    PubMed    
    
    
    
65. GHOSH S, Breitscheidel L, Lazarevic N, Martin A, et al
    Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update.
    Eur Respir J. 2021;57.
    PubMed     Abstract available
    
    
    
66. MAYNARD-SMITH L, Brown CS, Harris RJ, Hodkinson P, et al
    Effectiveness and outcomes of air travel-related TB incident follow-up: a systematic review.
    Eur Respir J. 2021;57.
    PubMed     Abstract available
    
    
    April 2021
67. VEZIRIS N, Bonnet I, Morel F, Guglielmetti L, et al
    Impact of the revised definition of extensively drug resistant tuberculosis.
    Eur Respir J. 2021 Apr 29. pii: 13993003.00641-2021.
    PubMed    
    
    
    
68. MUYOYETA M, Kerkhoff AD, Chilukutu L, Moreau E, et al
    Diagnostic accuracy of a novel point-of-care urine lipoarabinomannan assay for the detection of tuberculosis among adult outpatients in Zambia: a prospective cross-sectional study.
    Eur Respir J. 2021 Apr 29. pii: 13993003.03999-2020.
    PubMed     Abstract available
    
    
    
69. VAN DEUN A, Decroo T, Aung KJM, Hossain MA, et al
    Mycobacterium tuberculosis borderline rpoB mutations: emerging from the unknown.
    Eur Respir J. 2021 Apr 29. pii: 13993003.00783-2021.
    PubMed    
    
    
    
70. HAMADA Y, Cirillo DM, Matteelli A, Penn-Nicholson A, et al
    Tests for tuberculosis infection: landscape analysis.
    Eur Respir J. 2021 Apr 19. pii: 13993003.00167-2021.
    PubMed     Abstract available
    
    
    
71. VINEY K, Linh NN, Gegia M, Zignol M, et al
    New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization.
    Eur Respir J. 2021;57.
    PubMed    
    
    
    
72. SRIVASTAVA S, Gumbo T
    Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis.
    Eur Respir J. 2021;57.
    PubMed    
    
    
    
73. MAITRE T, Guglielmetti L, Veziris N
    Defining optimal fluoroquinolone exposure against Mycobacterium tuberculosis: contribution of murine studies.
    Eur Respir J. 2021;57.
    PubMed    
    
    
    
74. NORDHOLM AC, Lillebaek T
    It is time to optimise the management of latent tuberculosis infection in children.
    Eur Respir J. 2021;57.
    PubMed    
    
    
    March 2021
75. BOHLBRO AS, Hvingelby VS, Rudolf F, Wejse C, et al
    Active case-finding of tuberculosis in general populations and at-risk groups: a systematic review and meta-analysis.
    Eur Respir J. 2021 Mar 25. pii: 13993003.00090-2021.
    PubMed     Abstract available
    
    
    
76. GUPTA RK, Lule SA, Krutikov M, Gosce L, et al
    Screening for tuberculosis among high-risk groups attending London Emergency Departments: A prospective observational study.
    Eur Respir J. 2021 Mar 18. pii: 13993003.03831-2020.
    PubMed    
    
    
    
77. DE VRIES G, Gainaru D, Keizer S, Mahler B, et al
    Human reading versus computer automated reading of chest X-rays in a tuberculosis screening programme in Romania.
    Eur Respir J. 2021 Mar 10. pii: 13993003.04628-2020.
    PubMed    
    
    
    
78. JOUET A, Gaudin C, Badalato N, Allix-Beguec C, et al
    Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs.
    Eur Respir J. 2021;57.
    PubMed     Abstract available
    
    
    February 2021
79. HEYCKENDORF J, Marwitz S, Reimann M, Avsar K, et al
    Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model.
    Eur Respir J. 2021 Feb 11. pii: 13993003.03492-2020.
    PubMed     Abstract available
    
    
    
80. ZHANG N, Savic RM, Boeree MJ, Peloquin C, et al
    Optimising pyrazinamide for the treatment of tuberculosis.
    Eur Respir J. 2021 Feb 4. pii: 13993003.02013-2020.
    PubMed     Abstract available
    
    
    
81. KOHLI M, MacLean E, Pai M, Schumacher SG, et al
    Diagnostic accuracy of centralised assays for TB detection and detection of resistance to rifampicin and isoniazid: a systematic review and meta-analysis.
    Eur Respir J. 2021;57.
    PubMed     Abstract available
    
    
    January 2021
82. HAMADA Y, den Boon S, Maria Cirillo D, Penn-Nicholson A, et al
    Framework for the evaluation of new tests for tuberculosis infection.
    Eur Respir J. 2021 Jan 21. pii: 13993003.04078-2020.
    PubMed     Abstract available
    
    
    
83. SOULEYMANE MB, Piubello A, Lawan IM, Hassane-Harouna S, et al
    High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss.
    Eur Respir J. 2021;57.
    PubMed     Abstract available
    
    
    
84. RADTKE KK, Hibma JE, Hesseling AC, Savic RM, et al
    Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children.
    Eur Respir J. 2021;57.
    PubMed    
    
    
    December 2020
85. CHESOV D, Heyckendorf J, Alexandru S, Donica A, et al
    Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country.
    Eur Respir J. 2020 Dec 17. pii: 13993003.02544-2020.
    PubMed     Abstract available
    
    
    November 2020
86. MIRZAYEV F, Viney K, Linh NN, Gonzalez-Angulo L, et al
    World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
    Eur Respir J. 2020 Nov 26. pii: 13993003.03300-2020.
    PubMed     Abstract available
    
    
    
87. NIKOLAYEVSKYY V, Holicka Y, van Soolingen D, van der Werf MJ, et al
    Impact of COVID-19 pandemic on tuberculosis laboratory services in Europe.
    Eur Respir J. 2020 Nov 12. pii: 13993003.03890-2020.
    PubMed    
    
    
    
88. DAVIES FORSMAN L, Niward K, Kuhlin J, Zheng X, et al
    Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China.
    Eur Respir J. 2020 Nov 5. pii: 13993003.03463-2020.
    PubMed    
    
    
    
89. GEBRESELASSIE N, Kasaeva T, Zignol M
    A global strategy for tuberculosis research and innovation.
    Eur Respir J. 2020;56.
    PubMed    
    
    
    October 2020
90. MANDALAKAS AM, Hesseling AC, Kay A, Du Preez K, et al
    Tuberculosis prevention in children: A prospective community based study in South Africa.
    Eur Respir J. 2020 Oct 29. pii: 13993003.03028-2020.
    PubMed     Abstract available
    
    
    
91. GUPTA N, Ish P, Gupta A, Malhotra N, et al
    A profile of a retrospective cohort of 22 patients of COVID-19 with active/treated tuberculosis.
    Eur Respir J. 2020 Oct 22. pii: 13993003.03408-2020.
    PubMed    
    
    
    
92. KWON YS, Jeon D, Kang H, Yim JJ, et al
    Concurrent Use of Bedaquiline and Delamanid for the Treatment of Fluoroquinolone-resistant Multidrug-resistant Tuberculosis: A Nationwide Cohort Study in South Korea.
    Eur Respir J. 2020 Oct 22. pii: 13993003.03026-2020.
    PubMed    
    
    
    September 2020
93. CHIANG CY, Islam T, Xu C, Chinnayah T, et al
    The impact of COVID-19 and the restoration of tuberculosis services in the Western Pacific Region (revised).
    Eur Respir J. 2020 Sep 25. pii: 13993003.03054-2020.
    PubMed    
    
    
    May 2020
94. WONG YJ, Lee SWH
    We must screen refugees to ensure no one is left behind: a case study of Malaysia.
    Eur Respir J. 2020;55.
    PubMed    
    
    
    
95. VAN DEN ELSEN SHJ, Akkerman OW, Jongedijk EM, Wessels M, et al
    Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin.
    Eur Respir J. 2020;55.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge.